Oramed Pharmaceuticals Inc.
ORMP
$2.12
-$0.05-2.30%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -14.06% | 29.39% | 1.09% | -56.25% | -35.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.61% | 119.45% | -7.27% | 6.77% | -29.79% |
| Operating Income | 20.61% | -51.92% | 7.27% | -6.77% | 17.30% |
| Income Before Tax | 21.18% | -560.10% | -173.58% | -463.61% | 925.44% |
| Income Tax Expenses | -107.71% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 44.07% | -598.17% | -176.71% | -498.11% | 800.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 250.00% | -- | -75.00% | -62.90% | -93.28% |
| Net Income | 44.25% | -597.53% | -176.40% | -508.91% | 871.52% |
| EBIT | 20.61% | -51.92% | 7.27% | -6.77% | 17.30% |
| EBITDA | 20.19% | -53.82% | 6.80% | -6.97% | 17.60% |
| EPS Basic | 41.53% | -593.09% | -176.12% | -501.88% | 857.24% |
| Normalized Basic EPS | 32.93% | -69.48% | 22.86% | -473.78% | -91.95% |
| EPS Diluted | 40.91% | -605.32% | -181.22% | -501.88% | 833.33% |
| Normalized Diluted EPS | 33.13% | -72.28% | 20.83% | -473.78% | -89.08% |
| Average Basic Shares Outstanding | 1.91% | 0.96% | 0.36% | 1.11% | 1.83% |
| Average Diluted Shares Outstanding | 2.45% | -0.81% | -2.07% | 1.11% | 3.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |